153 related articles for article (PubMed ID: 2618654)
21. Local conditions in the host influence immunotherapy with interleukin-2 and LAK cells.
Steller EP; Ottow RT; Eggermont AM; Marquet RL; Sugarbaker PH
Cancer Detect Prev; 1988; 12(1-6):81-90. PubMed ID: 3263202
[TBL] [Abstract][Full Text] [Related]
22. Immunotherapy of liver metastases of human gastric carcinoma with interleukin 2-activated natural killer cells.
Yasumura S; Lin WC; Hirabayashi H; Vujanovic NL; Herberman RB; Whiteside TL
Cancer Res; 1994 Jul; 54(14):3808-16. PubMed ID: 8033100
[TBL] [Abstract][Full Text] [Related]
23. Immunogenicity of the tumor determines the outcome of immunotherapy with interleukin-2, ABPP, and cyclophosphamide of micro- and macrometastatic intraperitoneal tumor.
Eggermont AM; Sugarbaker PH
Cancer Detect Prev; 1990; 14(4):483-90. PubMed ID: 2224911
[TBL] [Abstract][Full Text] [Related]
24. Therapy of advanced solid tumors in mice using chemotherapy in combination with interleukin-2 with and without lymphokine-activated killer cells.
Kedar E; Ben-Aziz R; Shiloni E
Isr J Med Sci; 1988; 24(9-10):494-504. PubMed ID: 3264551
[TBL] [Abstract][Full Text] [Related]
25. The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.
Mulé JJ; Yang J; Shu S; Rosenberg SA
J Immunol; 1986 May; 136(10):3899-909. PubMed ID: 2871106
[TBL] [Abstract][Full Text] [Related]
26. Human cytotoxic T-cell lines with restricted specificity for squamous cell carcinoma of the head and neck.
Yasumura S; Hirabayashi H; Schwartz DR; Toso JF; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1993 Mar; 53(6):1461-8. PubMed ID: 8443824
[TBL] [Abstract][Full Text] [Related]
27. Combined therapy of mice bearing a lymphokine-activated killer-resistant tumor with recombinant interleukin 2 and an antitumor monoclonal antibody capable of inducing antibody-dependent cellular cytotoxicity.
Kawase I; Komuta K; Hara H; Inoue T; Hosoe S; Ikeda T; Shirasaka T; Yokota S; Tanio Y; Masuno T
Cancer Res; 1988 Mar; 48(5):1173-9. PubMed ID: 3257715
[TBL] [Abstract][Full Text] [Related]
28. Perilymphatic injections of cytokines: a new tool in active cancer immunotherapy. Experimental rationale and clinical findings.
Forni G; Giovarelli M; Jemma C; Bosco MC; Caretto P; Modesti A; Santoni A; Forni M; Cortesina G; de Stefani A
Ann Ist Super Sanita; 1990; 26(3-4):397-409. PubMed ID: 2151108
[TBL] [Abstract][Full Text] [Related]
29. Induction of tumor regression in experimental model of human head and neck cancer by human A-LAK cells and IL-2.
Sacchi M; Vitolo D; Sedlmayr P; Rabinowich H; Johnson JT; Herberman RB; Whiteside TL
Int J Cancer; 1991 Mar; 47(5):784-91. PubMed ID: 2004859
[TBL] [Abstract][Full Text] [Related]
30. Generation of an autologous cell system for immunotherapy of squamous cell carcinoma of the head and neck.
Mayer A; Andratschke M; Pauli C; Graefe H; Kristina K; Wollenberg B
Anticancer Res; 2005; 25(6B):4075-80. PubMed ID: 16309201
[TBL] [Abstract][Full Text] [Related]
31. Immunotherapy of murine sarcomas using lymphokine activated killer cells: optimization of the schedule and route of administration of recombinant interleukin-2.
Ettinghausen SE; Rosenberg SA
Cancer Res; 1986 Jun; 46(6):2784-92. PubMed ID: 3486038
[TBL] [Abstract][Full Text] [Related]
32. Effect of immunotherapy with allogeneic lymphokine-activated killer cells and recombinant interleukin 2 on established pulmonary and hepatic metastases in mice.
Shiloni E; Lafreniere R; Mulé JJ; Schwarz SL; Rosenberg SA
Cancer Res; 1986 Nov; 46(11):5633-40. PubMed ID: 3489526
[TBL] [Abstract][Full Text] [Related]
33. Interleukin 4 receptor-directed cytotoxin therapy for human head and neck squamous cell carcinoma in animal models.
Strome SE; Kawakami K; Alejandro D; Voss S; Kasperbauer JL; Salomao D; Chen L; Maki RA; Puri RK
Clin Cancer Res; 2002 Jan; 8(1):281-6. PubMed ID: 11801570
[TBL] [Abstract][Full Text] [Related]
34. Potent effector function of tumor-sensitized L-selectin(low) T cells against subcutaneous tumors requires LFA-1 co-stimulation.
Seeley BM; Barthel SW; To WC; Kjaergaard J; Shu S; Plautz GE
Otolaryngol Head Neck Surg; 2001 Apr; 124(4):436-41. PubMed ID: 11283503
[TBL] [Abstract][Full Text] [Related]
35. Biology, cytogenetics, and sensitivity to immunological effector cells of new head and neck squamous cell carcinoma lines.
Heo DS; Snyderman C; Gollin SM; Pan S; Walker E; Deka R; Barnes EL; Johnson JT; Herberman RB; Whiteside TL
Cancer Res; 1989 Sep; 49(18):5167-75. PubMed ID: 2766286
[TBL] [Abstract][Full Text] [Related]
36. Antitumor efficacy of lymphokine-activated killer cells and recombinant interleukin-2 in vivo: survival benefit and mechanisms of tumor escape in mice undergoing immunotherapy.
Mulé JJ; Ettinghausen SE; Spiess PJ; Shu S; Rosenberg SA
Cancer Res; 1986 Feb; 46(2):676-83. PubMed ID: 3484431
[TBL] [Abstract][Full Text] [Related]
37. Immunotherapy of cancer by systemic administration of lymphoid cells plus interleukin-2.
Rosenberg SA
J Biol Response Mod; 1984 Oct; 3(5):501-11. PubMed ID: 6389777
[TBL] [Abstract][Full Text] [Related]
38. [The anti-tumor efficacy of human recombinant interleukin-2 (rIL-2) in vivo].
Wang C; Chai L; Zhu G
Zhonghua Zhong Liu Za Zhi; 1995 Jan; 17(1):27-9. PubMed ID: 7656782
[TBL] [Abstract][Full Text] [Related]
39. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
[TBL] [Abstract][Full Text] [Related]
40. Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.
Forni G; Giovarelli M; Santoni A
J Immunol; 1985 Feb; 134(2):1305-11. PubMed ID: 3871210
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
